APHB - AmpliPhi Biosciences Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
0.3300
+0.0075 (+2.33%)
At close: 3:57PM EDT

0.3200 -0.02 (-5.30%)
After hours: 6:12PM EDT

Stock chart is not supported by your current browser
Previous Close0.3225
Open0.3380
Bid0.3100 x 800
Ask0.3550 x 1100
Day's Range0.3175 - 0.3400
52 Week Range0.3175 - 2.0500
Volume1,069,772
Avg. Volume427,938
Market Cap5.435M
Beta (3Y Monthly)3.13
PE Ratio (TTM)N/A
EPS (TTM)-0.7730
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • Business Wireyesterday

    AmpliPhi Biosciences Announces Closing of Public Offering

    AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the closing of its previously announced underwritten public offering. AmpliPhi sold 17,000,000 shares of common stock, or pre-funded warrants in lieu thereof, including 462,500 shares sold pursuant to the partial exercise of the underwriter’s option to purchase additional shares, and common warrants to purchase 17,500,000 shares of common stock, including common warrants to purchase 962,500 shares sold pursuant to the underwriter’s partial exercise of its option to purchase additional common warrants.

  • Business Wire6 days ago

    AmpliPhi Biosciences Announces Pricing of $6.6 Million Underwritten Public Offering

    AmpliPhi Biosciences Corporation (NYSE AMERICAN: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for patients with serious and life-threatening antibiotic-resistant bacterial infections, today announced the pricing of an underwritten public offering of 16,537,500 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), and common warrants to purchase up to an aggregate of 16,537,500 shares of common stock. Each share of common stock and, as applicable, pre-funded warrant is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $0.40 per share and accompanying common warrant.

  • Business Wire10 days ago

    AmpliPhi Biosciences Announces Presentation of Positive Clinical Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

    SAN DIEGO-- -- 13 patients with serious and life-threatening S. aureus infections were treated with AB-SA01 at the Westmead Hospital in Sydney under AmpliPhi’s expanded access program Patients suffered from severe S. aureus bacteremia and sepsis, including infective endocarditis and prosthetic valve endocarditis 83% patients in the modified intent-to-treat population achieved treatment success at the ...

  • Zacks Small Cap Research21 days ago

    APHB: Continued Success for Expanded Access Program; Ready to Initiate Clinical Trials for AB-SA01…

    On September 17, 2018, AmpliPhi Biosciences Corp. (APHB) announced updated results from the company’s use of its lead bacteriophage product candidates AB-SA01 and AB-PA01 through the expanded access program. To date, a total of 21 patients with serious or life-threatening infections not responding to standard antibiotic treatments have been treated at seven hospitals.

  • Business Wire24 days ago

    AmpliPhi Biosciences to Present Clinical Case Series Data at IDWeek 2018

    SAN DIEGO-- -- Professor Jonathan Iredell to present data from AmpliPhi Biosciences’ ongoing expanded access program for bacteriophage product candidates AB-SA01 and AB-PA01 AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that clinical case series data from the company’s ...

  • Business Wirelast month

    AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-PA01 Targeting Pseudomonas Aeruginosa Infections

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration (FDA) regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.

  • Business Wirelast month

    AmpliPhi Biosciences Announces Positive FDA Feedback for its Clinical Stage Bacteriophage Product Candidate AB-SA01

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company had a Type B Pre-IND meeting with the U.S. Food and Drug Administration (FDA) and has now received the meeting minutes. Based on the FDA’s feedback, AmpliPhi currently plans to initiate the first randomized clinical trial of its AB-SA01 bacteriophage therapy product candidate in early 2019.

  • Business Wirelast month

    AmpliPhi Biosciences Announces Updated Positive Clinical Results for its Expanded Access Program

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced updated topline clinical results for its ongoing single-patient expanded access program. 84% of patients achieved treatment success (physician’s assessment) at the end of therapy, defined as complete resolution or significant improvement of baseline signs and symptoms.

  • Why You Need To Look At This Factor Before Buying AmpliPhi Biosciences Corporation (NYSEMKT:APHB)
    Simply Wall St.last month

    Why You Need To Look At This Factor Before Buying AmpliPhi Biosciences Corporation (NYSEMKT:APHB)

    Anyone researching AmpliPhi Biosciences Corporation (NYSEMKT:APHB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory.Read More...

  • Zacks Small Cap Research2 months ago

    APHB: Meeting with the FDA Soon to Establish Path Forward for AB-SA01 and AB-PA01…

    The company reported that a total of 19 patients with serious or life-threatening infections have been treated with either AB-SA01 or AB-PA01 at a total of seven hospitals. As the company had previously guided, the goal was to get data on approximately 20 patients and then approach the FDA to get guidance on a regulatory path forward and design of Phase 2 trials for AB-SA01 and AB-PA01. AmpliPhi will be meeting with the FDA in August and September 2018 to do just that.

  • Business Wire2 months ago

    AmpliPhi Biosciences Reports Second Quarter 2018 Financial Results and Business Highlights

    SAN DIEGO-- -- 19 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have been treated with AB-SA01 or AB-PA01 under single-patient expanded access program AmpliPhi has scheduled meetings with the FDA in August and September to discuss the regulatory path forward for AB-SA01 and AB-PA01 AmpliPhi Biosciences Corporation , a clinical-stage biotechnology ...

  • Zacks Small Cap Research4 months ago

    APHB: Successful Case Reports Presented for AB-SA01 and AB-PA01

    On June 7, 2018, AmpliPhi Biosciences Corp. (APHB) reported that multiple case reports on patients treated with the company’s lead bacteriophage development products, AB-SA01 and AB-PA01, were presented at the American Society of Microbiology (ASM) Annual Meeting and the 41st European Cystic Fibrosis Conference. Topline results from these cases had previously been announced by AmpliPhi with the presentations providing additional details.

  • Business Wire4 months ago

    AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Studies at American Society of Microbiology Annual Meeting

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a late-breaker poster presentation describing four case studies of patients suffering from severe Staphylococcus aureus (S.

  • Business Wire4 months ago

    AmpliPhi Biosciences Announces Presentation of AB-PA01 Bacteriophage Therapy Case Study at 41st European Cystic Fibrosis Conference

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced a poster presentation of a successful case study of a patient with cystic fibrosis, suffering from recurrent multi-drug resistant Pseudomonas aeruginosa (P.

  • Did AmpliPhi Biosciences Corporation’s (NYSEMKT:APHB) Earnings Growth Outperform The Industry?
    Simply Wall St.5 months ago

    Did AmpliPhi Biosciences Corporation’s (NYSEMKT:APHB) Earnings Growth Outperform The Industry?

    Analyzing AmpliPhi Biosciences Corporation’s (AMEX:APHB) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations,Read More...

  • Business Wire5 months ago

    AmpliPhi Biosciences to Present at 5th World Congress on Targeting Infectious Diseases: Targeting Phage & Antibiotic Resistance 2018

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced its participation in the 5th World Congress on Targeting Infectious Diseases – Targeting Phage and Antibiotic Resistance, Phage Therapy and Other Innovative Ideas (TID 2018). The conference is being held May 17-18, 2018 in Florence, Italy.

  • Zacks Small Cap Research5 months ago

    APHB: Case Study on AB-PA01 Presented at ISHLT Annual Meeting

    On April 3, 2018, AmpliPhi Biosciences Corp. (APHB) announced a case study involving a lung transplant patient that was administered AB-PA01 as part of a treatment for a resistant Pseudomonas aeruginosa lung infection was presented at the International Society for Hearth and Lung Transplantation 38th Annual Meeting. This is an excellent example of the ability of bacteriophage therapy to treat recurrent infections while not having any long-term negative impact on the normal flora. Six out of the seven patients (86%) achieved “treatment success”, which was defined as complete resolution or significant improvement of baseline signs and symptoms.

  • Business Wire5 months ago

    AmpliPhi Biosciences Reports First Quarter 2018 Financial Results and Business Highlights

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced financial results for the first quarter ended March 31, 2018.

  • AmpliPhi Biosciences Corporation’s (NYSEMKT:APHB) Shift From Loss To Profit
    Simply Wall St.5 months ago

    AmpliPhi Biosciences Corporation’s (NYSEMKT:APHB) Shift From Loss To Profit

    AmpliPhi Biosciences Corporation’s (AMEX:APHB): AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. On 31 December 2017, the US$18.11M market-cap postedRead More...

  • ACCESSWIRE5 months ago

    Free Technical Insights on Aimmune Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want a free Stock Review on AIMT sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.

  • Business Wire5 months ago

    AmpliPhi Biosciences to Hold 2018 First Quarter and Business Update Conference Call on May 15

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, today announced that management will hold a business update conference call on Tuesday, May 15, 2018 beginning at 4:30 p.m.

  • Business Wire5 months ago

    AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will utilize the Therapeutic Development Services funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to conduct further preclinical studies of AB-SA01. The Therapeutic Development Services program funds the provision of preclinical services for selected companies and researchers in order to advance development of promising interventional agents.

  • Business Wire7 months ago

    AmpliPhi Biosciences Announces Presentation of Bacteriophage Therapy Case Study at ISHLT Annual Meeting

    AmpliPhi Biosciences Corporation , a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation of a case study of a lung transplant recipient suffering from a resistant Pseudomonas aeruginosa lung infection who received treatment with bacteriophage therapeutics, including AB-PA01.

  • Zacks Small Cap Research7 months ago

    APHB: Expecting to Meet with FDA in mid-2018 to Determine Regulatory Path Forward

    By David Bautz, PhD NYSE:APHB Business Update Positive Interim Results for Single-Patient Expanded Access Program On January 3, 2018, AmpliPhi Biosciences Corp. (NYSE:APHB) announced positive interim results ...

  • Business Wire7 months ago

    AmpliPhi Biosciences Announces Closing of Registered Direct Offering of Common Stock

    AmpliPhi Biosciences Corporation , a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced the closing of its previously announced registered direct offering of 2,743,640 shares of its common stock at a price of $1.10 per share.